Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Starboard’s Opportunistic Buying Of Commvault

By March 12, when the S&P 500 Index was already down 15% and lockdowns in response to the COVID-19 pandemic were starting to become normalized, new activist stakes slowed to a minimum. Excluding governance-only campaigners and companies below $100 million in market-capitalization, there have been just over 20 in the past three weeks – many of those the result of months or years of work or re-entries, such Starbucks and Chef’s Warehouse, where activists retreated to what they know.

Amidst the noise, Starboard Value’s purchase of a 9.3% stake in Commvault Systems (NASDAQ:CVLT) shows what opportunistic buying might look like. The hedge fund was buying call options at the end of February, according to a regulatory filing, but started buying the data management company’s shares in earnest as it began to recover from its lows after March 18 – stopping nine days later.

Starboard did not respond to a request for comment. A Commvault spokeswoman wouldn’t comment on whether Starboard had engaged with the board or management team but told me the company “embraces open dialogue with our entire shareholder community and will continue to act in their best interest.”

Jeff Smith Starboard Value

Activist Insight Vulnerability had suggested that this former target of Elliott Management might soon find itself in the crosshairs of an activist again as recently as January, after it shrugged off gains during Elliott’s time as a major shareholder (between April 2018 and February 2019, the company surrendered two board seats and its poison pill).

Indeed, Elliott’s prior involvement may have been part of the appeal. Companies coming under fire from different dedicated activists at separate times are rare but hardly unheard of, with about 15 instances where the first campaign started in 2018 or later, according to Activist Insight Online.

Elliott’s run at Commvault showed how high the stock could trade and kickstarted the refreshment of four out of 11 director spots, including a new CEO and chairman. Operating expenses, one of Elliott’s key targets, came down about 2% in 2019 and were on course for a similar fall this fiscal year, after three quarters.

But that may not be enough for Starboard, which tends to target big improvements and is not averse to changing large numbers of directors. The other six directors have between 12 and 23 years of tenure, according to Activist Insight Governance. Given that the company’s nomination deadline isn’t until April 13 and Starboard has kept two proxy contests in play – even justifying them with reference to the pandemic – a further board challenge is not out of the question.

The challenge will be finding a remedy, perhaps further incremental change or a sale to private equity. With that industry apparently focused on existing positions, dealmaking has all but dried up. Who knows if it will be back before markets start to shudder from the prospect of a recession?

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.